Histogenics Corp (NASDAQ:HSGX) shares shot up 5.9% on Monday . The company traded as high as $0.18 and last traded at $0.18. 3,583,650 shares changed hands during trading, a decline of 65% from the average session volume of 10,373,892 shares. The stock had previously closed at $0.17.
Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC acquired a new position in Histogenics during the fourth quarter worth $25,000. Virtu Financial LLC grew its holdings in Histogenics by 505.8% during the first quarter. Virtu Financial LLC now owns 592,976 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 495,096 shares during the period. Finally, Sabby Management LLC acquired a new position in Histogenics during the first quarter worth $220,000. 7.97% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Histogenics (HSGX) Shares Up 5.9%” was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/4347678/histogenics-hsgx-shares-up-5-9.html.
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Recommended Story: What is an Initial Public Offering (IPO)?
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.